Engene to present at the leerink partners global biopharma conference

Boston and montreal , march 5, 2024 /prnewswire/ - engene holdings inc. (nasdaq: engn) or "engene" or the "company"), a clinical-stage genetic medicines company whose non-viral lead program eg-70 is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced that jason hanson, chief executive officer, will present at the leerink partners global biopharma conference in miami, fl on march 13, 2024, at 8:40 a.m. et. a live webcast of the presentation can be accessed under the investors section of the engene website at www.engene.com/presentations and will be archived there for 90 days.
ENGN Ratings Summary
ENGN Quant Ranking